Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma ...Middle East

OSLO, Norway, Aug. 3, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R...

Hence then, the article about nordic nanovector provides update on paradigme its phase 2b pivotal trial with betalutin in r r follicular lymphoma was published today ( Wednesday 04/08/2021 - 02:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma )

Also on site :

• 'It was unlike anything I'd witnessed before': Orcas seen headbutting a sunfish so hard that it exploded
• Nordic Capital announces agreement to sell ArisGlobal to Dassault Systèmes, following its transformation into a scaled and AI-enabled life sciences platform
• Primoris Services Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRIM